As the six approved CAR-T cell therapies, including Breyanzi®, Abecma™ and CARVYKTI™ are poised to achieve blockbuster status, along with a promising development pipeline, the field of CAR-T cell therapies has gained significant traction
Roots Analysis is pleased to announce the publication of its recent study, titled, “Global CAR-T Cell Therapy Market (4th Edition), 2022-2035.”
The study features an in-depth analysis of key drivers and trends related to this domain. Amongst other elements, the report includes:
§ A detailed assessment of the current market landscape of CAR-T-cell therapies.
§ An analysis of key insights derived from the study featuring a competitive analysis, highlighting the popular target antigens related to hematological malignancies and solid tumors.
§ A detailed analysis of completed, ongoing and planned clinical studies related to CAR-T cell therapies.
§ An insightful analysis highlighting the key opinion leaders (KOLs) in this domain featuring an analysis of the various principal investigators of clinical trials related to CAR-T cell therapies.
§ Elaborate profiles of marketed and mid- to late-stage clinical products (phase I/II or above).
§ An analysis of various type of partnership that have been inked between several stakeholders in the domain of CAR-T-cell therapies.
§ An analysis of the investments that have been made into companies that have proprietary CAR-T cell-based products / technologies.
§ An in-depth analysis of patents related to CAR-T cell therapies, filed / granted till 2022.
§ A case study on manufacturing cell therapy products, highlighting the key challenges, and a detailed list of contract service providers and in-house manufacturers involved in this space.
§ An elaborate discussion on various factors that form the basis for the pricing of cell-based therapies.
§ A review of the key promotional strategies being adopted by the developers of the approved CAR-T cell therapies.
§ Elaborate profiles of the several leading players in the domain of CAR-T cell therapies.
A detailed market forecast, featuring analysis of the current and projected future opportunity across key market segments (listed below):
§ Target Indication(s)
§ Non-Hodgkin’s Lymphoma
§ Multiple Myeloma
§ Acute Lymphoblastic Leukemia
§ Chronic Lymphocytic Leukemia
§ Hodgkin’s Lymphoma
§ Acute Myeloid Leukemia
§ Ovarian Cancer
§ Generalized Myasthenia Gravis (MG)
§ Renal Cell Carcinoma
§ Target Antigen
§ CD19
§ BCMA
§ CD19/22
§ Others
§ Key Geographical Regions
§ North America
§ Europe
§ Asia Pacific
§ Latin America
§ Middle East and North Africa
§ Rest of the World
Transcripts of interviews held with the following senior level representatives of stakeholder companies:
§ Troels Jordansen (Chief Executive Officer, Glycostem Therapeutics)
§ Wei (William) Cao (Chief Executive Officer, Gracell Biotechnologies)
§ Miguel Forte (Chief Operating Officer, TxCell)
§ Adrian Bot (Vice President, Scientific Affairs, Kite Pharma)
§ Vincent Brichard (Vice President, Immuno-Oncology, Celyad)
§ Brian Dattilo (Manager of Business Development, Waisman Biomanufacturing)
§ Aino Kalervo (Former Competitive Intelligence Manager, Strategy & Business Development, Theravectys)
§ Xian-Bao Zhan (Professor of Medicine and Director, Department of Oncology, Changhai Hospital)
§ Enkhtsetseg Purev (Assistant Professor of Medicine, University of Colorado)
The research includes profiles of key players (listed below); each profile features a brief overview of the company, details related to its financial information (if available), details about CAR-T-cell based product(s), such as information on type of therapy and current development status, information on technology portfolio (if available), recent developments related to CAR-T cell immunotherapies and manufacturing capabilities of the players.
§ Autolus
§ bluebird Bio
§ Bristol Myers Squibb
§ Carsgen Therapeutics
§ Cellectis
§ Cellular Biomedicine Group
§ Gilead Sciences
§ Innovative Cellular Therapeutics
§ Kuur Therapeutics
§ Noile-Immune Biotech
§ Novartis
§ Shanghai GeneChem
§ Sinobioway Cell Therapy
§ Takara Bio
§ Wellington Zhaotai Therapies
Get more details on the CAR-T Cell Therapy Market report https://www.rootsanalysis.com/reports/view_document/car-t-therapies-market/269.html
You may also be interested in the following titles:
Quantum Computing in Drug Discovery Services Market
You may also like to learn what our experts are sharing in Roots educational series:
| mRNA Synthesis: Manufacturing Process of Modern Revolutionary Molecule |
About Roots Analysis
Roots Analysis is a global leader in the pharma / biotech market research. Having worked with over 750 clients worldwide, including Fortune 500 companies, start-ups, academia, venture capitalists and strategic investors for more than a decade, we offer a highly analytical / data-driven perspective to a network of over 450,000 senior industry stakeholders looking for credible market insights.
Contact:
Ben Johnson
+1 (415) 800 3415
Arabic
French
Spanish
Portuguese
Deutsch
Turkish
Dutch
Italiano
Russian
Romaian
Portuguese (Brazil)
Greek